NYSE American has accepted Picard Medical's compliance plan to address delisting risks related to stockholders' equity and recent financial losses. The company previously reported a stockholders' deficit of $1.4 million as of March 31, 2026, and losses in three of its four most recent fiscal years. This acceptance allows the company to maintain its listing on the NYSE American under the ticker PMI through a compliance period ending November 8, 2027, subject to quarterly reviews and the achievement of specific milestones. Picard Medical is a medical device company that develops and commercializes total artificial heart technology.

Picard Medical, Inc. announced a 1-for-50 reverse stock split to support continued compliance with NYSE American listing standards. The split was approved by stockholders on July 17, 2026, and is scheduled to become effective at 5:00 PM ET on July 31, 2026. Following the split, the company's common stock will begin trading on a split-adjusted basis on August 3, 2026, under the existing symbol "PMI" with a new CUSIP number 71953R 207. Picard Medical is a medical device company that manufactures the SynCardia Total Artificial Heart.

At its July 17, 2026 Annual Meeting, Picard Medical, Inc. stockholders approved several material charter amendments. The company is now authorized to execute a reverse stock split at a ratio between 1-for-15 and 1-for-50, with the final ratio and timing to be determined by the Board of Directors. Additionally, stockholders approved the designation of Class B common stock, which carries 20 votes per share. Other approved items included the election of directors Richard Fang, Sam Van, Joe Xiao, and George Ye, the ratification of MaloneBailey LLP as the 2026 independent auditor, and an annual frequency for advisory votes on executive compensation. The company operates in the medical industry and provides healthcare-related products or services.